

DRUG NAME: Epirubicin**SYNONYM(S):** 4'-epiDOXOrubicin,¹ IMI-28,¹ NSC-256942¹**COMMON TRADE NAME(S):** PHARMORUBICIN®,² ELLENCE®³**CLASSIFICATION:** anthracycline antineoplastic antibiotic⁴**MECHANISM OF ACTION:**

The mechanism of action of epirubicin appears to be related to its ability to bind to nucleic acids.² It forms a complex with DNA by intercalation between base pairs, resulting in inhibition of DNA and RNA synthesis.⁴ Intercalation also triggers DNA cleavage by topoisomerase II, resulting in cytotoxic activity.^{3,4} Binding to cell membranes and plasma proteins may also be involved.² Epirubicin also generates cytotoxic free radicals.^{3,4} Epirubicin is the 4'-epimer of DOXOrubicin; i.e., there is a different spatial orientation of the hydroxyl group at the 4' carbon of the sugar moiety.⁴ This difference may account for faster elimination and reduced toxicity.²

PHARMACOKINETICS:

Distribution	rapidly and widely distributed into tissues ³ ; may concentrate in red blood cells, whole blood concentrations are approximately twice those of plasma ³	
	cross blood brain barrier?	no
	volume of distribution ³	21-27 L/kg
	plasma protein binding ³	77%
Metabolism	extensive hepatic metabolism; also metabolized by other organs and cells, including red blood cells ³	
	active metabolite(s)	epirubicinol (13-OH epirubicin) ³ ; cytotoxic activity one-tenth that of epirubicin; plasma levels consistently lower than epirubicin
	inactive metabolite(s)	glucuronides of epirubicin and epirubicinol; DOXOrubicin; aglycones of doxorubicinol, 7-deoxydoxorubicin, and 7-deoxydoxorubicinol ³
Excretion	predominantly hepatobiliary; rapid elimination of parent compound from plasma	
	urine	9-10% within 48 h ² ; 20-27% within 4 days ³
	feces	40% of dose recovered in bile within 72 h
	terminal half life ³	33 h
	clearance ³	65-83 L/h
Gender	no differences observed ³	
Elderly	clearance may be decreased in elderly women ³	

Adapted from standard reference³ unless specified otherwise.**USES:****Primary uses:**

- * Breast cancer
- * Gastric cancer
- * Lung cancer, non-small cell
- * Lung cancer, small cell
- * Lymphoma, Hodgkin's
- * Lymphoma, non-Hodgkin's
- * Ovarian cancer
- *Health Canada approved indication

Other uses:

- Bladder cancer^{5,6}
- Pediatric, soft tissue sarcoma⁷
- Soft tissue sarcoma⁸⁻¹⁰

SPECIAL PRECAUTIONS:

Contraindicated in patients with the following conditions³:

- hypersensitivity to epirubicin or any component of the product
- hypersensitivity to other anthracyclines (e.g., DAUNOrubicin, DOXOrubicin)
- hypersensitivity to anthracenediones (e.g., mitoXANTRONE, mitomycin)
- severe hepatic impairment
- severe myocardial insufficiency
- recent myocardial infarction
- severe arrhythmias
- history of severe cardiac disease
- previous therapy with high cumulative doses of anthracyclines (e.g., DOXOrubicin, DAUNOrubicin, epirubicin, IDArubicin)
- previous therapy with high cumulative doses of some anthracenediones (e.g., mitoXANTRONE)

Cardiac toxicity is a risk of epirubicin therapy that may be manifested by early (acute) or late (delayed) effects.⁴ Cardiac function should be assessed at baseline and continue during treatment; refer to Side Effects section for more information. Risk factors for developing epirubicin-induced cardiotoxicity include³:

- high cumulative dose, previous therapy with other anthracyclines or anthracenediones
- prior or concomitant radiotherapy to the mediastinal/pericardial area
- pre-existing heart disease
- concomitant use of drugs that can suppress cardiac contraction

Carcinogenicity: Epirubicin has been associated with an increased risk of secondary leukemia in human trials.³

Mutagenicity: Epirubicin is mutagenic and clastogenic in animals, and may induce chromosomal damage in human spermatozoa.³

Fertility: Dose-related infertility has been observed in mammals of both sexes.³ Epirubicin may cause premature menopause in premenopausal women.

Pregnancy: FDA Pregnancy Category D.³ There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. Chemotherapy protocols including epirubicin have been administered during pregnancy to treat breast cancer.¹¹⁻¹⁵ For more information, please refer to The BC Cancer Agency Cancer Management Guidelines for Breast Cancer in Pregnancy.

Breastfeeding is not recommended due to the potential secretion into breast milk.

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.¹⁶

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <i>bold, italics</i>	
allergy/immunology	anaphylaxis
	chills, fever, shock, urticaria
blood/bone marrow/	anemia (13-72%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
febrile neutropenia	leukopenia (50-80%, severe 2-59%), neutropenia (54-80%, severe 10-67%); nadir 10-14 days after treatment; recovery by day 21
	neutropenic fever (6%)
	thrombocytopenia (5-49%)
cardiovascular (arrhythmia)	acute transient ECG changes, sinus tachycardia; see discussion following table
cardiovascular (general)	congestive heart failure , symptomatic ³ (0.9-3.3%, dose-related); risk increases steeply after cumulative dose of 900 mg/m ² ; see paragraph following Side Effects table
	decreased left ventricular ejection fraction, asymptomatic (1-3%); see paragraph following Side Effects table
	thromboembolism (including fatal pulmonary embolism), thrombophlebitis, venous sclerosis
constitutional symptoms	fever (1-5%)
	fatigue/lethargy (1-46%)
	malaise/asthenia
dermatology/skin	<i>extravasation hazard: vesicant</i>
	alopecia (70-96%), regrowth occurs 2-3 months after discontinuing epirubicin therapy ³
	flushing
	injection site reactions (2-20%)
	photosensitivity
	radiation recall reaction
	rash/itch (1-9%)
	skin changes (1-5%)
skin and nail hyperpigmentation	
endocrine	hot flashes(5-39%)
gastrointestinal	<i>emetogenic potential: dose-related¹⁷; high-moderate for > 90 mg/m², low-moderate for ≤ 90 mg/m²</i>
	anorexia (2-3%)
	dehydration
	diarrhea (7-25%)
	dyspepsia
	hyperpigmentation of the oral mucosa
	mucositis (9-58%)
nausea/vomiting (83-92%)	
hemorrhage	bleeding, GI
hepatic	increased transaminases ¹⁸
infection	infection (15-22%)
metabolic/laboratory	hyperuricemia
ocular/visual	conjunctivitis (1-15%), keratitis

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
renal/genitourinary	red colouration of urine for 1-2 days after administration
secondary malignancy	acute myeloid leukemia, myelodysplastic syndrome (0.3-0.6%)
sexual/reproductive function	amenorrhea (69-72%), premature menopause
syndromes	tumour lysis syndrome

Adapted from standard reference³ unless specified otherwise.

Cardiotoxicity is thought to be due to free radical damage as myocardial tissue is susceptible to these highly reactive species.¹⁹ Anthracycline cardiotoxicity may present with early or late effects.^{20,21} The following information applies to all anthracyclines, anthracenediones and mitoXANTRONE.^{19,21,22}

Early cardiotoxic effects are not dose-related and may present from mild ECG changes to life-threatening arrhythmias.^{19,20,22} These events may occur during or immediately after a single dose of anthracycline treatment,^{19,22} but do not predict subsequent development of delayed cardiotoxicity and are not considered indications for suspension of therapy.^{19,20,22-25}

Late cardiotoxic effects, which are dose-related and clinically the most important type of cardiotoxic effect, present as reduced LVEF or symptomatic CHF, and typically occur weeks to years after completion of treatment.^{19,21-24} Abnormalities in LVEF are associated with all the anthracyclines and their derivatives.²¹ LVEF changes are related to the total cumulative dose, are irreversible and refractory to medical therapy.^{19,26}

Prevention and treatment. Cardiac assessment should occur at baseline and throughout therapy. Monitor for symptomatic congestive heart failure (CHF) or reduced left ventricular ejection fraction (LVEF). Sensitive, non-invasive methods to measure LVEF include radionucleotide angiography (RNA), MUGA, or echocardiogram.²¹ Late cardiotoxic effects may be prevented by stopping treatment with the associated anthracycline once patients have reached the suggested maximum cumulative dose.^{19,26} Management of anthracycline cardiotoxicity includes discontinuation of the drug and initiating standard treatment of CHF.²¹

Cardiotoxicity risk can be reduced but not eliminated with the use of alternative anthracyclines (i.e., epirubicin or liposomal DOXOrubicin) or by altering the frequency of administration (once a week vs. once every 3 weeks, or continuous infusion).²¹ Cardioprotectant therapy with dexrazoxane may be considered for patients with cumulative DOXOrubicin-equivalent doses greater than 300 mg/m².^{2,22,27,28}

Cumulative doses should be calculated using the following table, taking into account all previous anthracyclines or anthracenediones received during the patient's lifetime.

AGENT	SUGGESTED CONVERSION FACTOR TO DOXORUBICIN DOSE ^{29-31*}	SUGGESTED MONITORING THRESHOLD ^{20,21,32**}
DAUNOrubicin	x 0.5-0.83	450 mg/m ²
DOXOrubicin	x 1	300 mg/m ²
epirubicin	x 0.5-0.67	600 mg/m ²
IDArubicin	x 2-5	150 mg/m ²
mitoXANTRONE	x 2.2-4	not defined

* based on relative hematological toxicities³⁰

** Treatment may continue beyond these doses in selected patients, if the clinician has considered the potential risks and benefits. The addition of dexrazoxane may be considered, and monitoring should be increased. Maximum tolerated doses are variable;

some patients may tolerate DOXOrubicin equivalent doses exceeding 1000 mg/m² while other patients exhibit symptomatic CHF at DOXOrubicin equivalent doses less than 300 mg/m².

Local effects: Extravasation of epirubicin can occur with or without accompanying stinging or burning sensation, and even if blood returns well on aspiration of the infusion needle.³ Severe local tissue necrosis may occur. To minimize the risk of thrombosis or perivenous extravasation, the usual administration time should be 15 to 20 minutes, and never less than 3 minutes.³ For more information on prevention and treatment of extravasation with DOXOrubicin refer to BC Cancer Agency Provincial Systemic Therapy Program: Prevention and Management of Extravasation of Chemotherapy. Also, monitor for local erythematous streaking along vein and/or facial flushing which may indicate a too rapid infusion rate.³³ This has traditionally been called the “epirubicin flare.”^{34,35}

Hyperuricemia may result from cell lysis by cytotoxic chemotherapy and may lead to electrolyte disturbances or acute renal failure.³⁶ It is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas, and myeloproliferative diseases. The risk may be increased in patients with preexisting renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients³⁷:

- aggressive hydration: 3 L/m²/24 hr with target urine output >100 ml/h
- if possible, discontinue drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitor electrolytes, calcium, phosphate, renal function, LDH, and uric acid q6h x 24-48 hours
- replace electrolytes as required
- allopurinol 600 mg po initially, then 300 mg po q6h x6 doses, then 300 mg po daily x 5-7 days

Urine should be alkalinized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH>7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalinization of the urine.³⁸ It may be used for treatment or prophylaxis of hyperuricemia; however, its place in therapy has not yet been established. Aluminium hydroxide (AMPHOGEL®) may be added orally if phosphate becomes elevated. If aluminium hydroxide has been added, discontinue sodium bicarbonate.³⁹

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
bevacizumab ⁴⁰	anthracycline-induced cardiotoxicity may be increased	unknown	monitor cardiac function throughout treatment
calcium channel blockers (e.g., verapamil) ^{2,4}	anthracycline-induced cardiotoxicity may be increased	additive toxicity	monitor cardiac function throughout treatment
cimetidine ^{2,3,41}	increases AUC of epirubicin by 50% and decreases clearance of epirubicin by 30%	unknown; does not seem to be related to cytochrome P450	discontinue cimetidine and choose alternate therapy; e.g., ranitidine
gemcitabine ⁴²	no influence on epirubicin pharmacokinetics		
taxanes ⁴²⁻⁴⁸ (e.g., DOCEtaxel, PACLitaxel)	toxicity of both agents may be increased when given concurrently, regardless of which drug is given first; lower neutrophil and platelet nadirs, and slower neutrophil recovery have been observed	increased levels of epirubicin metabolites, decreased taxane clearance	separate administration by 24 hours if possible
trastuzumab ⁴⁹	anthracycline-induced cardiotoxicity may be increased	unknown	monitor cardiac function throughout treatment

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.